503614-92-4

Basic information

• Product Name: 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid
• Synonyms: 1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c];1H-Pyrazolo[3,4-c]pyridine-3-carboxylic acid, 4,5,6,7-tetrahydro-1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl]-;1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid;4,5,6,7-tetrahydro-1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl]-1H-Pyrazolo[3,4-c]pyridine-3-carboxylic acid;Apixaban Carboxylic Acid;Apixaban Carboxylic Acid Impurity;Apixaban Impurity A (BMS-591455-01);1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4
• CAS NO: 503614-92-4
• Molecular Formula: C₂₅H₂₄N₄O₅
• Molecular Weight: 460.48186
• EINECS: -0
• Mol File: 503614-92-4.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 807.247 °C at 760 mmHg
• Flash Point: 442.007 °C
• Appearance: /
• Density: 1.42
• Storage Temp.: 2-8°C
• Solubility: Chloroform (Slightly)
• PKA: 3.51±0.20(Predicted)
• CAS DataBase Reference: 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid(503614-92-4)
• EPA Substance Registry System: 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid(503614-92-4)

Safety Data

• Hazardous Substances Data: 503614-92-4(Hazardous Substances Data)

Usage

Description

1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid is a complex organic compound with a unique chemical structure. It is an intermediate in the synthesis of Apixaban, a medication used to prevent blood clots.

Uses

Used in Pharmaceutical Industry:
1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid is used as an intermediate in the synthesis of Apixaban (A726700) for its role as an inhibitor of blood coagulation factor Xa. This application is significant in the development of anticoagulant medications, which are crucial for the prevention and treatment of various cardiovascular conditions, such as deep vein thrombosis, pulmonary embolism, and stroke.

Upstream product

• 675-20-7 piperidin-2-one 
• 473927-64-9 1-(4-methoxy-phenyl)-6-(4-iodo-phenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester 
• 27143-07-3 ethyl 2-chloro-2-(2-(4-methoxyphenyl)hydrazono)acetate 
• 473927-69-4 1-(4-iodo-phenyl)-3-morpholin-4-yl-5,6-dihydro-1H-pyridin-2-one 
• 545445-44-1 5,6?dihydro?3?(4?morpholinyl)?1?[4?(2?oxo?1?piperidinyl)phenyl]?2(1H)?pyridone 
• 104-94-9 4-methoxy-aniline 
• 881386-01-2 3,3-dichloro-1-(4-nitrophenyl)piperidine-2-one 
• 1039914-85-6 5-chloro-N-(4-nitrophenyl)pentanamide 
• 1575-61-7 5-Chlorovaleroyl chloride 
• 1421823-20-2 ethyl 6-(4-(N-(4-chlorobutyl)carboxamido)phenyl)-1-(4-methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate 
• 536759-91-8 4,5,6,7-tetrahydro-1-(4-methoxyphenyl)-6-(4-nitrophenyl)-7-oxo- 1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester 
• 503615-03-0 3-(morpholin-4-yl)-1-(4-nitrophenyl)-5,6-dihydropyridin-2(1H)-one 
• 454183-28-9 3-(4-nitrophenylamino)propionic acid ethyl ester 
• 100-01-6 4-nitro-aniline 

Downstream Products

• 503612-88-2 1-(4-methoxyphenyl)-3-methyl-6-[4-(2-oxopiperidin-1-yl)-phenyl]-1,4,5,6-tetrahydropyrazolo[3,4-c]pyridin-7-one 
• 1074365-84-6 methyl 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazole-[3,4-c]pyridine-3-carboxylate 

Relevant articles and documents

Method for Preparation of Apixaban

The present invention relates to a novel method for manufacturing apixaban. According to the method of the present invention, the method does not use expensive reagents or solvents, thereby being economical. In addition, there is no special condition or complicated process, and dangerous reagents or solvents are not used, thus the method is easy for mass-production industrially. Furthermore, since no toxic solvents are used in the final step of the synthesis and purification of apixaban, it is possible to manufacture a high purity apixaban with a high yield without the risk of residual solvent.COPYRIGHT KIPO 2020

Design, synthesis, and biological activity of novel tetrahydropyrazolopyridone derivatives as FXa inhibitors with potent anticoagulant activity

A series of novel tetrahydropyrazolopyridone derivatives containing 1,3,4-triazole, triazolylmethyl, and partially saturated heterocyclic moieties as P2 binding element was designed, synthesized, and evaluated in vitro for anticoagulant activity in human and rabbit plasma. All compounds showed moderate to significant potency, and compounds 15b, 15c, 20b, 20c, and 22b were further examined for their inhibitory activity against human FXa in vitro. While compounds 15c and 22b were tested for rat venous thrombosis in vivo. The most promising compound 15c, with an IC50 (FXa) value of 0.14?μM and 98% inhibition rate, warranted further investigation as an FXa inhibitor.

LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS

The present application describes lactam-containing compounds and derivatives thereof of Formula I: P4—P-M-M4??I or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.